39 results about "Acute inflammatory reaction" patented technology

Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and / or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and / or inflammatory disease, or an acute inflammatory reaction. Thus methods of treatment include administering a sufficient amount of a compound or salt as provided herein to decrease the symptoms or slow the progression of these diseases. Other embodiments include methods of treating other animals, including livestock and domesticated companion animals, suffering from a disease responsive to inhibition of kinase activity. Methods of treatment include administering a compound of Formula I-a as a single active agent or administering a compound of Formula I-a in combination with one or more other therapeutic agent. A method for determining the presence of Btk in a sample, comprising contacting the sample with a compound or form thereof of Formula I-a under conditions that permit detection of Btk activity, detecting a level of Btk activity in the sample, and therefrom determining the presence or absence of Btk in the sample.

Compounds of Formula Iand all pharmaceutically acceptable forms thereof, are described herein.The variables R1, R2, R3, Z2, and Q, shown in Formula I are defined herein.Pharmaceutical compositions containing one or more compounds of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein.Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and / or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and / or inflammatory disease, or an acute inflammatory reaction. Thus methods of treatment include administering a sufficient amount of a compound or salt as provided herein to decrease the symptoms or slow the progression of these diseases.Other embodiments include methods of treating other animals, including livestock and domesticated companion animals, suffering from a disease responsive to inhibition of kinase activity.Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agent.A method for determining the presence of Btk in a sample, comprising contacting the sample with a compound or form thereof of Formula I under conditions that permit detection of Btk activity, detecting a level of Btk activity in the sample, and therefrom determining the presence or absence of Btk in the sample.

Described are methods and compositions that inhibit IL-1 signalling for the treatment of acute inflammatory response to cell necrosis, and the attendant collateral tissue damage.

The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. Methods for making an anti-factor XI monoclonal antibody, or epitope-binding fragments, variants, or derivatives thereof, are also provided.

The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. Methods for making an anti-factor XI monoclonal antibody, or epitope-binding fragments, variants, or derivatives thereof, are also provided.

The invention discloses a panda source lactobacillus plantarum and application. The strain was preserved in China Center for Type Culture Collection on May 4, 2016 and the preservation number is CCTCC NO: M2016245. The panda source lactobacillus plantarum provided by the invention can be used for improving antibody levels of IgA, IgM and IgG immune globulins of blood serum; a condition that the percent of lymphocytes is reduced and the percent of neutrophils is increased, caused by infection and induction of enterotoxigenic escherichia coli, is inhibited; expression levels of inflammation related factors IL-1beta, IL-8, IL-6, TLR4 and MyD88mRNA (messenger Ribonucleic Acid) are remarkably down-regulated, and intestinal acute inflammation response caused by the enterotoxigenic escherichia coli is alleviated.

The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting substrate metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction on an organism. The sequence of the polypeptide is Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu which is a brand new sequence (D-Pyr is D-type pyridine alanine, D-Cys isD-type cysteine, and Bip is diphenyl alanine). The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate of an endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.

Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM as a result of the nitric oxide sequestration by PEM. Nitric oxide sequestration may cause a reduction in available extracellular nitric oxide in the tumor endothelium, which may prompt a widespread shutdown of vascular flow, hemorrhage, and necrosis. In particular, shutdown of vascular flow may trigger changes in nitric oxide production as well as trigger an acute inflammatory response, which may create reactive nitrogen species that are particularly destructive to the microvasculature. PEM constructs are developed that incorporate large amounts of iron-containing protein, possess high oxygen affinities, and demonstrate delayed nitric oxide binding. Such properties induce selective NME of tumors after extravasation, and will likely enhance the effect of VEGFR TKIs and / or mTOR inhibitors.

The invention relates to the field of drugs and in particular relates to polypeptides capable of inhibiting matrix metalloproteinase-2 and tumor necrosis factor liberase and also capable of relieving damage of acute inflammatory reaction to an organism. The sequence of the polypeptides is Trp-Ser-Asn-Val-Gly-Gly-Gly-Gly-Glu-Lys-Met, which is a brand new sequence; the polypeptides are capable of inhibiting the activities of matrix metalloproteinase-2 and the tumor necrosis factor liberase in vitro on the level of 1 micromole, and also capable of increasing the survival rate of endotoxic shock mice in in vivo tests; the polypeptides have potential new drug development value.

The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting substrate metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction to an organism. The sequence of the polypeptide is Pro-Arg-Cys-(D-Bip)-(D-Arg)-Gly-Glu which is a brand new sequence (D-Bip is D-type diphenyl alanine, and D-Arg is D-type arginine). The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate of an endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.

The invention discloses a plasma filter capable of adsorbing OFRs (oxygen free radicals) and belongs to the field of health care. The plasma filter comprises a casing, wherein a liquid inlet and a liquid outlet are arranged at two ends of the casing respectively; filter elements made from positive charge films are mounted in the casing and comprise a roll type filter element close to the liquid inlet and a planar filter element close to the liquid outlet. The plasma filter adopts the manner of adsorbing plasma through the positive charge films and can directly and quickly remove the OFRs in blood, through combination of the roll type filter element and the planar filter element, plasma is smooth, the filtering surface area is further increased, and the filtering effect is improved. The plasma filter is arranged in an in-vitro plasma adsorbing system and can be medically clinically used conveniently and efficiently, and a new treatment method is provided for quick solution of acute inflammatory reactions.

The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction on an organism. The sequence of the polypeptide is Pro-Arg-(D-Cys)-Bip-Arg-Gly-Glu (Bip is D-type diphenyl alanine, D-Cys is D-type cysteine), which is a brand new sequence. The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate ofan endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.

Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM as a result of the nitric oxide sequestration by PEM. Nitric oxide sequestration may cause a reduction in available extracellular nitric oxide in the tumor endothelium, which may prompt a widespread shutdown of vascular flow, hemorrhage, and necrosis. In particular, shutdown of vascular flow may trigger changes in nitric oxide production as well as trigger an acute inflammatory response, which may create reactive nitrogen species that are particularly destructive to the microvasculature. PEM constructs are developed that incorporate large amounts of iron-containing protein, possess high oxygen affinities, and demonstrate delayed nitric oxide binding. Such properties induce selective NME of tumors after extravasation, and will likely enhance the effect of VEGFR TKIs and / or mTOR inhibitors.

The invention relates to the field of medicaments, in particular to a polypeptide for inhibiting matrix metalloproteinase-9 and tumor necrosis factor kallikrein and reducing destroy on an organism by acute inflammatory reaction. A sequence of the polypeptide is Pro-(D-Pyr)-(D-Cys)-Bip-(D-Cys)-Gly-Glu and is a brand new sequence, wherein Bip is biphenyl alanine, D-Pyr is D-type pyridine alanine, and D-cys is D-type cysteine; the activities of the matrix metalloproteinase-9 and the tumor necrosis factor kallikrein can be inhibited in vitro at the level of 1 micromole; the survival rate of mice undergoing endotoxic shock is increased during an in-vivo test; and the polypeptide has a potential novel medicament development value.

A novel equine P-selectin glycoprotein ligand-1 (ePSGL-1) is disclosed having the amino acid sequence set forth in SEQ ID NO:2. DNA sequences encoding the ePSGL-1 are also disclosed, along with vectors, host cells, and methods of making the ePSGL-1. The invention further provides methods for preventing or reducing acute inflammatory response in an equine subject by administering ePSGL-1 and fragments thereof (e.g., an ePSGL-1-Ig fusion protein). The invention also provides methods for identifying compounds capable of reducing or preventing damage to tissue or organs caused by acute inflammatory response in an equine subject.

The present invention pertains to a liquid nutritional composition comprising fat and proteinaceous matter, wherein said fat contributes for at least 41 En% and said proteinaceous matter contributes for at least 23 En% to the total energy content of said composition, for mitigating, attenuating or preventing an acute inflammatory response during or after surgery of a patient undergoing said surgery, wherein said composition is to be administered to said patient by intra-operative tube feeding,as well as to specific liquid nutritional compositions, suitable for use as a tube feed,and especially for mitigating, attenuating or preventing an acute inflammatory response during or after surgery of a patient.

The invention relates to the field of drugs, and particularly relates to a compound capable of inhibiting proteasomes and relieving damage of an acute inflammatory reaction to bodies. The compound has the molecular structure of syringic acid-(4-hydroxy-3,5-dimethoxybenzoic acid), can increase the survival rate of endotoxic shock mice in in-vivo tests, and has potential new drug development value.

The invention relates to the field of drugs and particularly relates to a polypeptide capable of activating natural killer T cells, inhibiting matrix metalloproteinases-2 and relieving destruction of acute inflammatory reaction to an organism. The polypeptide has the sequence as follows: RQQQEATRPRTAAANGLMQT which is a brand new sequence. The polypeptide can be used for inhibiting the activity of matrix metalloproteinases-2 in vitro and increasing the survival rate of endotoxin shock rats in an in-vivo test so as to have a potential novel drug development value.

The invention belongs to the technical field of biological medicines, and discloses an Actinobacillus pleuropneumoniae gene, and prokaryotic expression and application of a protein. An App7 type bacterial strain genome is taken as a template to carry out amplification to obtain the whole-genome sequence of AdhE; and a pET-32a(+)-rAdhE prokaryotic expression carrier is successfully constructed, soluble inducible expression of the pET-32a(+)-rAdhE prokaryotic expression carrier in escherichia coli BL21 is realized, and the size of a fusion protein is 110kDa. ELISA detection proves that the prokaryotic expression rAdhE fusion protein can stimulate a mouse to generate a high-level specific antibody, and immunogenicity is good; and after the mouse is immunized by rAdhE, the mouse can resist App7 type lethality virus attacking and 70% of APP1 type virus attacking protection, and the in vivo acute inflammatory reaction of the mouse is lightened.

The invention particularly relates to a traditional Chinese medicine composite capable of performing detoxification and relieving a sore throat, and a preparation method and application of the traditional Chinese medicine composite. The traditional Chinese medicine composite comprises the following active ingredients in parts by weight: 7-23 parts of calyx seu fructus physalis, 7-23 parts of radix isatidis, 4-17 parts of common andrographis herb, 4-17 parts of fructus arctii, 2-11 parts of platycodon grandiflorum, 2-11 parts of mint and 4-17 parts of glycyrrhiza uralensis. The traditional Chinese medicine composite has a better treatment effect on acute pharyngitis lesions of multiple trial young experimental animals; an inhibition effect on inflammatory factor secretion and non-specificity acute inflammatory reaction is possibly an important link of the traditional Chinese medicine composite for treating acute pharyngitis; an antipyretic effect of the traditional Chinese medicine composite can also improve a clinical fever symptom to a certain extent.

The invention discloses an application of combination of furosemide and dexamethasone in treating early severe acute pancreatitis. In fluid resuscitation, through the application of the combination of the furosemide and and dexamethasone in coordination with natural plasma (human plasma), fluid balance is achieved and parenteral nutrition is supplemented, and meanwhile, capillary leakage is reduced and intra-abdominal hypertension and acute inflammatory reaction are relieved; after the fluid resuscitation, in coordination with parenteral nutrition, early intestinal perfusion is conducted by virtue of a nasal jejunal feeding tube, so as to promote intestinal peristalsis and also to maintain intestinal mucosa nutritional substrate; therefore, the biggest lymph laboratory of human body is kept stable, atrophy and bacterial translocation of the lymph laboratory are relieved, exhaustion and defecation are promoted and abdominal distension is relieved; and in addition, intravenous medication and liquid amount can be obviously reduced, and transformation from fluid balance to negative-water balance is achieved so as to protect organ functions and to relieve the occurrence of complications.

The invention relates to the field of drugs, and particularly relates to a compound capable of inhibiting proteasomes and relieving damage of an acute inflammatory reaction to bodies. The compound has the molecular structure of 3'-methoxy benzyl-4-hydroxy-3,5-dimethoxy-benzoate, can increase the survival rate of endotoxic shock mice in in-vivo tests, and has potential new drug development value.

The invention relates to the field of drugs and particularly relates to a polypeptide capable of activating natural killer T cells, inhibiting matrix metalloproteinases-9 and relieving destruction of acute inflammatory reaction to an organism. The polypeptide has the sequence as follows: VVHPLSSARWGGRR which is a brand new sequence. The polypeptide can be used for inhibiting the activity of matrix metalloproteinases-2 in vitro on the level of 1 micromole and increasing the survival rate of endotoxin shock rats in an in-vivo test so as to have a potential novel drug development value.

The invention provides an application of aphanothece sacrum polysaccharidein preparation of a medicine for treating scalds. When being used for treating scalds, the aphanothece sacrum polysaccharidein can lower the IL-1beta level, relieve acute inflammatory response, lower the content of Col I and increase the content of Col III in the healing process, so that scars are not easy to leave after wounds are healed.